About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Psychiatry, Mental Health and Addictions Research Group at the Vall d'Hebron Research Institute is a multidisciplinary team that over the past 13 years has focused its scientific activity on the research (both nationally and internationally) of clinical, therapeutic and etiopathogenic aspects of:
At international level, it participates and/or coordinates several European projects of great repercussion in the area of mental health. At national level, it is part of the CIBERSAM (Centre for Biomedical Research in Mental Health Network) together with other leading groups, conducting research of excellence.
PMID: 37944280 Journal: Journal of Stroke & Cerebrovascular Diseases Year: 2023 Reference: J Stroke Cerebrovasc Dis. 2023 Nov 7;33(1):107467. doi: 10.1016/j.jstrokecerebrovasdis.2023.107467. Impact factor: Publication type: Paper in international publication Authors: Agudelo, Victor Hugo; Alonso, Javier Robles; Alvarez, Maria Eugenia Vazquez; Amat-Santos, Ignacio J; Andraka, Leire; Anton, Salvador Alvarez; Aquino, Rosa Sanchez; Arellano, Manuel Vizcaino; Arroyo, Jose Ramon Ruiz; Arzamendi, Dabit et al. DOI: 10.1016/j.jstrokecerebrovasdis.2023.107467
PMID: 37995122 Journal: JMIR formative research Year: 2023 Reference: JMIR Form Res. 2023 Nov 23;7:e34232. doi: 10.2196/34232. Impact factor: Publication type: Paper in international publication Authors: Castellano-Tejedor, Carmina; Gartner, Silvia; Ginchev, Todor; Haukkala, Ari; Iglesias Serrano, Ignacio; Izquierdo, Ana Diez; Khattak, Fida; Knittle, Keegan; Lusilla-Palacios, Pilar; Messa, Ines Mir et al. DOI: 10.2196/34232
PMID: 38003562 Journal: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES Year: 2023 Reference: Int J Mol Sci. 2023 Nov 15;24(22):16372. doi: 10.3390/ijms242216372. Impact factor: Publication type: Paper in international publication Authors: Aguinaco, Reyes; Astigarraga, Itziar; Bastida, Jose Maria; Bernardo, Angel; Carrasco, Marina; Castellano-Tejedor, Carmina; Closa, Laia; Corrales, Irene; Ferrero, Ainara; Garcia-Martinez, Iris et al. DOI: 10.3390/ijms242216372
PMID: 38039690 Journal: JOURNAL OF PSYCHIATRIC RESEARCH Year: 2023 Reference: J Psychiatr Res. 2023 Nov 18;169:160-165. doi: 10.1016/j.jpsychires.2023.11.018. Impact factor: Publication type: Paper in international publication Authors: Amoretti, Silvia; B Menezes, Ana Maria; Barros, Fernando C; Goncalves, Helen; Kapczinski, Flavio; Kunz, Mauricio; Marchionatti, Lauro Estivalete; Passos, Ives Cavalcante; Rabelo-da-Ponte, Francisco Diego; Roza, Thiago Henrique et al. DOI: 10.1016/j.jpsychires.2023.11.018
PMID: 33613322 Journal: Frontiers in Physiology Year: 2021 Reference: Front Physiol. 2021 Feb 5;12:628236. doi: 10.3389/fphys.2021.628236. eCollection 2021. Impact factor: 4.566 Publication type: Paper in international publication Authors: Rizzuto, Valeria, Koopmann, Tamara T, Blanco-Alvarez, Adoracion, Tazon-Vega, Barbara, Idrizovic, Amira, Diaz de Heredia, Cristina, Del Orbe, Rafael, Pampliega, Miriam Vara, Velasco, Pablo, Santen, Gijs W E et al. DOI: 10.3389/fphys.2021.628236
PMID: 33616199 Journal: REVISTA DE NEUROLOGIA Year: 2021 Reference: Rev Neurol. 2021 Mar 1;72(5):168-176. doi: 10.33588/rn.7205.2020639. Impact factor: 0.87 Publication type: Review in national publication Authors: Gomez-Barros, N, Ramos-Quiroga, J A, Vidal, R, Nieto-Fernandez, Z et al. DOI: 10.33588/rn.7205.2020639
PMID: 32281520 Journal: Transcultural Psychiatry Year: 2021 Reference: Transcult Psychiatry. 2021 Feb;58(1):126-139. doi: 10.1177/1363461520916697. Epub 2020 Apr 11. Impact factor: 2.221 Publication type: Paper in international publication Authors: Collazos, Francisco, Malagon-Amor, Angeles, Falgas-Bague, Irene, Qureshi, Adil, Gines, Jose Maria, Del Mar Ramos, Maria, McPeck, Samantha, Hussain, Isra, Wang, Ye, Alegria, Margarita et al. DOI: 10.1177/1363461520916697
PMID: 33589642 Journal: Nature Communications Year: 2021 Reference: Nat Commun. 2021 Feb 15;12(1):1166. doi: 10.1038/s41467-021-21566-w. Impact factor: 14.919 Publication type: Letter or abstract Authors: Havdahl, Alexandra, Neale, Benjamin M, Franke, Barbara, Faraone, Stephen V, Borglum, Anders D, Andreassen, Ole A, Arranz, Maria Jesus, Banaschewski, Tobias, Bau, Claiton, Bellgrove, Mark et al. DOI: 10.1038/s41467-021-21566-w
Irritability in ADHD and BDP is an understudied symptom that has a major impact on patients' quality of life and may even increase the risk of suicide.
These results reinforce the need for more individualized attention to address educational needs from an early stage.
On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.
